We thought pharma needed better AI models. It actually needed better systems.
Most pharma teams can build a good model. Scaling it across real workflows is where things break, especially in pharmacovigilance. The problem isn’t prediction. It’s coordination.
That’s where the idea of an Agent Factory comes in. Instead of one AI tool, you have a system of agents, each handling a specific task like translation, extraction, or coding, while an orchestrator decides whether the output is good enough or needs human review.
This changes everything. Workflows move from sequential to parallel. Processing shifts from hours to seconds. Humans stop reviewing everything and focus only on edge cases.
The real unlock isn’t automation alone. It’s auditability. Every decision is traceable, explainable, and reviewable, which is critical in regulated environments like pharma.
Feels like the shift is from tools to systems, and from outputs to decisions.
If you want a deeper breakdown, this explains it well:
https://capestart.com/technology-blog/agent-factory-in-pharma/
The real shift is exactly that:
regulated AI stops being judged on output quality first.
It gets judged on whether the system can survive scrutiny.
In pharma, a strong model is table stakes.
What actually gets bought is traceability, escalation logic, and whether the workflow can hold up under audit.
That’s the point where “better AI” stops being the pitch.
And “safer operational infrastructure” becomes the product.